This article has Open Peer Review reports available.
Downregulation of TFPI in breast cancer cells induces tyrosine phosphorylation signaling and increases metastatic growth by stimulating cell motility
© Stavik et al; licensee BioMed Central Ltd. 2011
Received: 7 March 2011
Accepted: 17 August 2011
Published: 17 August 2011
Increased hemostatic activity is common in many cancer types and often causes additional complications and even death. Circumstantial evidence suggests that tissue factor pathway inhibitor-1 (TFPI) plays a role in cancer development. We recently reported that downregulation of TFPI inhibited apoptosis in a breast cancer cell line. In this study, we investigated the effects of TFPI on self-sustained growth and motility of these cells, and of another invasive breast cancer cell type (MDA-MB-231).
Stable cell lines with TFPI (both α and β) and only TFPIβ downregulated were created using RNA interference technology. We investigated the ability of the transduced cells to grow, when seeded at low densities, and to form colonies, along with metastatic characteristics such as adhesion, migration and invasion.
Downregulation of TFPI was associated with increased self-sustained cell growth. An increase in cell attachment and spreading was observed to collagen type I, together with elevated levels of integrin α2. Downregulation of TFPI also stimulated migration and invasion of cells, and elevated MMP activity was involved in the increased invasion observed. Surprisingly, equivalent results were observed when TFPIβ was downregulated, revealing a novel function of this isoform in cancer metastasis.
Our results suggest an anti-metastatic effect of TFPI and may provide a novel therapeutic approach in cancer.
KeywordsTFPI-1 adhesion migration invasion tumor suppressor
An association between cancer and the hemostatic system has been recognized for almost two centuries [1–3]. Thrombosis is nevertheless still among the leading causes of death in cancer patients . The coagulation cascade is triggered by tissue factor (TF) and results in the formation of a fibrin network. TF pathway inhibitor-1 (TFPI) is mainly known for its role in the hemostatic system where it is responsible for the inactivation of TF-induced coagulation [4, 5]. There is, however, a growing body of evidence of a new role of TFPI in cancer. Elevated levels of plasma TFPI in cancer patients have previously been reported [6, 7], and TFPI expression was demonstrated in several tumors, including breast cancer tissue and cells [8, 9], indicating a possible involvement of TFPI in cancer biology .
Two main isoforms of TFPI are recognized, TFPIα and TFPIβ. TFPIα consists of three Kunitz-type domains and a basic C-terminus, and is either secreted or attached to the cell membrane through an unknown glycosylphosphatidylinositol (GPI) linked molecule. TFPIβ contains only the first two Kunitz-domains and has a different C-terminus with a GPI anchor that attaches it to the cell membrane [10–13]. The functional role of TFPIβ is not yet completely understood . In a recent study, we demonstrated a pro-apoptotic effect of both TFPIα and TFPIβ in breast cancer cells in vitro, while corresponding downregulation of endogenous TFPI resulted in reduced apoptotic activity . It has previously been reported that treatment of cancer cells with TFPIα, either recombinant or through ectopic overexpression, resulted in reduced primary and metastatic tumor growth and tumor cell adhesion in murine models [16, 17]. The non-hemostatic activity of TFPIα has in several cases been reported to be dependent on the C-terminal part of the protein [18–23], and a peptide corresponding to the C-terminus of TFPIα has been shown to inhibit angiogenesis and tumor growth in vivo .
Requirements for malignant cancer cells to form metastases are to escape from the primary tumor, to passage through the circulatory system, and to establish secondary tumors at distant sites. Such movement requires abnormal growth and adhesion characteristics and penetration of the extracellular matrix (ECM) surrounding the tumor and vessel organs . Integrins are cell surface receptors involved in adhering cells to the ECM and mediate cell movement . Binding of the ligand mediates attachment to the matrix, while phosphorylation of the receptor relays spreading of the cells to the matrix  through the formation of filopodia, lamellipodia, and stress fibers . Matrix metalloproteinases (MMPs) are proteases which are able to cleave the ECM and basement membrane and are thus important for metastasis of cancer cells . In the present study, we investigated how downregulation of TFPI would affect the growth and metastatic abilities of human breast cancer cells in vitro, and the possible mechanisms involved. To investigate the significance of the C-terminal end of TFPIα, downregulation of only TFPIβ was conducted. We show here that lowered expression of both isoforms of TFPI or only TFPIβ induced cell signaling and self-sufficient growth, and stimulated adhesion, migration, and invasion of the cells. The increase in invasion was connected to elevated activity of the proteases MMP-2 and MMP-9.
Cell culture and stable cell lines
The intraductal breast carcinoma cells Sum102 were grown in Human mammary epithelial cell (HuMEC) ready medium (Invitrogen, Carlsbad, CA, USA) containing HuMEC supplements (epidermal growth factor, hydrocortisone, isoprotenerol, transferrin and insulin) and Bovine Pituitary Extract (Invitrogen). The human mammary adenocarcinoma cells MDA-MB-231 were grown in DMEM (Lonza, Viviere, Belgium) with 10% fetal bovine serum (FBS, Lonza). Cells were cultured at 37°C in an incubator with a humidified atmosphere and 5% CO2.
Stable cell lines with TFPI downregulated were established as previously described . In short, double stranded cDNAs encoding shRNAs targeting both isoforms of TFPI were cloned into the retroviral vector pSiRPG  and co-transfected into HEK293T cells together with viral helper vectors. Sum102 and MDA-MB-231 wild type cells were infected with the viral particles and positive clones were selected by the use of puromycin. The stable cell line pools with TFPI downregulated were named pSiRPG-shRNA4, -6 and -7. For downregulation of TFPIβ, cDNAs encoding shRNAs against this isoform were cloned into the pSiRPG vector and transduced into MDA-MB-231 cells (shRNA sequences available upon request). The resulting stable cell line pools were named pSiRPG-shRNA7β and -9β. Cell lines transduced with an empty vector were used as controls and named pSiRPG. The downregulation of TFPI was confirmed both at the mRNA and protein level using quantitative RT-PCR and total TFPI ELISA, respectively, as previously described . The self-designed Taqman assays TFPIα (fwd primer: 5'-CAAGAATGTCTGAGGGCATGTAAA-3', rev primer: 5'-CTGCTTCTTTCTTTTTCTTTTGGTTT-3', probe: 5'-AGGGTTTCATCCAAAGAATATCAAAAGGAGGCC-3') and TFPIβ (fwd primer: 5'-CAAGGTTCCCAGCCTTTTTGT-3', rev primer: 5'-CTTGGTAAATATGAGCCGCATTC-3', probe: 5'-TCCAACCATCATTTGTTCCTTCTTTTGT-3') were used for mRNA quantification of the individual isoforms.
To study the cells ability to grow when seeded at low densities, transduced Sum102 cells (0.2, 5, and 10·103) were seeded in 12-wells trays and grown for minimum 8 days without reaching confluence. Cells were washed once with phosphate buffered saline (PBS), trypsinized and counted using Nucleocounter (Chemometec, Alleroed, Denmark). In colony formation experiments, 6-wells trays were pre-coated with a 0.6% agar/medium mixture before 2.5·104 cells/well were seeded individually in 1.7 mL medium containing 0.35% agar. Cells were grown for 4-6 weeks until colonies appeared. Cells were incubated 1 hour with 100 μL of MTT for visualization before trays were scanned using a computer attached scanner (HP Scanjet 8200). Colonies were counted using the image processing and analysis program ImageJ version 18.104.22.168 (Rasband W; National Institute of Health, Bethesda, MD, http://rsbweb.nih.gov/ij/index.html).
Adhesion and cell spreading
Transduced cells were starved over night in medium without supplements (Sum102) or with 1% FBS (MDA-MB-231) and seeded (5/2.5·104; Sum102/MDA-MB-231) in 96-wells trays coated with fibronectin (10 μg/mL), laminin (10 μg/mL), collagen I or IV (10 μg/mL), vitronectin (0.5 μg/mL), or gelatin (2%). Plates were incubated for 30 minutes and washed gently once with growth medium. Adhered cells were counted indirectly by incubation in medium containing 10 μL WST-1 for 30 minutes followed by analysis at wavelengths 450 and 745 nm in a colorimetric plate reader (Benchmark Microplate Reader, BIO-RAD, Hercules, CA).
For cell spreading analyses, transduced cells were starved over night and seeded (3/1.5·105; Sum102/MDA-MB-231) on glass cover slips coated with fibronectin (10 μg/mL), laminin (10 μg/mL) or collagen I (10 μg/mL), and incubated for 1 hour at 37°C. Cells were washed once in PBS, fixed in 4% formaldehyde in PBS for 15 minutes at room temperature and washed three times in PBS. 0.1% Triton in 100x PBS was added, and after 4 minutes the cells were washed three times in PBS. Subsequently, the cells were dyed with 1% rhodamine-conjugated phalloidin (Invitrogen) for 30 minutes and washed twice in PBS and once in water before the cover slips were mounted on object glasses using flueric mounting medium (Vector Laboratories Inc., Burlingame, CA). Labeled actin was visualized using a fluorescence Nikon eclipse TE300 inverted microscope with a Plan Fluor ELWD 40x/0.60 NA objective (Nikon, Tokyo, Japan) and appropriate filters. Images were captured using a Nikon DS-5M-L1 Camera system. The cell spreading was quantified by measuring the area of the cells using ImageJ.
Transduced Sum102 cells were seeded in 6-wells trays and starved over night in medium without supplements. A wound was made in the confluent cell monolayer using sterile pipette tips and the cells were washed gently once with PBS before adding culture medium containing 5% serum. Images were captured after 0, 7.5, and 17 hours using a Nikon eclipse TE300 inverted microscope with a Plan 10x/0.25 NA objective (Nikon) and an attached Nikon DS-5M-L1 Camera system. The width of the wound was measured manually at each time point.
Cell migration and invasion
Migration of transduced Sum102 and MDA-MB-231 cells was assessed by a modified Boyden`s chamber method using a 24-wells format with transwell Falcon HTS Fluoro Blok inserts (8-μm pore size; Becton Dickinson, Franklin Lakes, NJ, USA). Cells were starved over night in medium without supplements (Sum102) or with 1% FBS (MBA-MB-231), detached with 5 mM EDTA in PBS and seeded (10/5·104; Sum102/MDA-MB-231) in 500 μL of starvation medium in the upper chambers of the transwell. 750 μL culture medium with 10% FBS was added to the lower chambers as a chemoattractant, and the cells were allowed to migrate for 24/16 hours (Sum102/MDA-MB-231) at 37°C. After incubation, the medium was removed and inserts washed once in Hank's Balanced Salt solution (HBSS). Cells were stained with Calcein AM for 90 minutes and migrated cells were detected using a bottom-reading fluorescence plate-reader (Wallac Victor 1420, Perkin Elmer, Waltham, MA) at excitation/emission wavelengths of 485/535 nm.
Invasion of transduced Sum102 and MDA-MB-231 cells was assessed as described for the migration assay, except for the usage of matrigel pre-coated inserts (BD BioCoat Tumor invasion system, Bedford, MA, USA). Cells were incubated for 48/24 hours (Sum102/MDA-MB-231) before labeling. For MMP inhibition experiments, doxycycline hyclate (6 μg/mL, Sigma-Aldrich, St. Louis, MO) was added to the upper chambers directly after cell seeding.
Transduced cells were seeded to reach 80% confluency after thee days and harvested as previously described . TFPI antigens were measured in the medium and lysate of cells with the commercial Asserachrom® Total and Free TFPI ELISA kits (Diagnostica Stago, Asnière, France), which detect both isoforms of TFPI or only TFPIα, respectively. Urokinase plasminogen activator (uPA) antigen levels and plasminogen activator inhibitor 1 (PAI-1) activity were measured in the medium of cells using the commercial ELISA kits Zymutest uPA antigen (Hyphen BioMed, Neuville-sur-Oise, France) and Trinilize PAI-1 Activity (Trinity Biotech, Jamestown, NY), respectively. Results were corrected against cellular total protein measured in the cell lysate.
MMP-2 and MMP-9 activity in conditioned medium collected from the transduced cells were determined by gelatin zymography. Sum102 (3.25·105) and MDA-MB-231 (4·105) cells were seeded in 6-wells trays and grown for three days before medium was collected and cells lysed in Tris (tris(hydroxymethyl)aminomethane) lysis buffer  for Western blot analysis of α-tubulin. For MDA-MB-231 cells, growth medium was replaced with serum-free AIM-V (Invitrogen) medium the day after seeding. The serum-free media were separated on 7.5% polyacrylamide gels containing 0.1% gelatin (type A from porcine skin, Sigma-Aldrich). After electrophoresis, gels were washed twice for 20 minutes in 2.5% Triton X-100 and incubated overnight at 37°C in 50 mm Tris (pH 7.5), 200 mm NaCl, 5 mm CaCl2 and 0.02% Brij 35 (Sigma-Aldrich). Positive controls for MMP-2 (recombinant, R&D Systems, Abingdon, UK) and MMP-9  were run with each gel. The gels were stained with 0.1% Coomassie Brilliant Blue R-250 and clear bands indicated gelatinolytic activity.
Transduced Sum102 and MDA-MB-231 cells (5·106) were distributed into Eppendorf tubes and washed twice with PBS. Cells were resuspended in 0.55 ml PBS or PBS containing phosphatidylinositol-phospholipase (PI-PLC, 0.7 U/mL, Sigma-Aldrich) and incubated for 2 hours at 37°C. After incubation the cells were pelleted and the supernatant collected. Cell pellets were washed twice in cold PBS and lysed. Cellular total protein was measured in the cell lysate and total and free TFPI antigens were measured in the supernatant as described above.
Western blot analysis
Transduced Sum102 and MDA-MB-231 cells were starved for 5.5 hours in medium without supplements and FBS, respectively. 1-2·106 cells were distributed into Eppendorf tubes and stimulated with growth medium containing 10% FBS for 0-60 minutes. Cells were washed twice in PBS and lysed in sample buffer containing 10% DTT, 0.25% Benzonase, 0.2% aprotinin, 0.6% 100 mM PMSF, and 1.0% phosphatase inhibitor cocktail and stored at -20°C until use. The cell lysates were incubated at 97°C for 5 minutes before separated on SDS-polyacrylamide gels (Bio-Rad Laboratories, Hercules, CA). Membranes were incubated with primary antibody over night at 4°C and 1 hour at room temperature with the appropriate horseradish peroxidase (HRP) -conjugated secondary antibody. HRP signals were developed using the ECL Plus Western blotting detection system (GE Healthcare Bio-Sciences, Uppsala, Sweden). The following human antibodies were used; Anti-phospho-Akt (Ser473, #9271), anti-phospho-IκB (Ser32, #2859), anti-phospho-NF-κB (Ser468, #3039), anti-phospho-44/42 MAPK (Thr202/Tyr204, #4377), anti-phospho-SAPK/JNK (Thr183/Tyr185, #9251), and anti-phospho-Src family (Tyr416, #2010) from Cell signaling Technology (Denver, MA), anti-phosphotyrosine HRP conjugate (clone 4G10, #16-105) from Millipore (Billerica, MA), anti-phosphotyrosine PY99 (sc-7020) from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-CD49b (integrin α2, 611016) from BD Biosciences (San Jose, Ca). Anti-c-Src (sc-8056, Santa Cruz Biotechnology) and anti-α-tubulin (#T5168, Sigma-Aldrich) were used as loading controls.
Statistical differences between data from cells with TFPI downregulated and empty vector pSiRPG control cells were calculated using Graphpad Prism 5.0 (Graphpad, San Diego, CA, USA). The unpaired student's t test was used after verification of the normal distribution of the data. The Welch's correction (for unequal variances) was applied when appropriate. For data not normally distributed, the non-parametric Mann-Whitney test was used. The statistical differences in cell migration at 7.5 and 17 hours and in invasion of untreated and doxycycline-treated cells were calculated using two-way ANOVA with Bonferroni corrected post-tests. A probability value (p) of < .05 was considered significant.
Stable cell lines with TFPI downregulated
Stable downregulation of both isoforms of TFPI in Sum102 and MDA-MB-231 breast cancer cells.
% of control
Total TFPI ag
Total TFPI ag,
Free TFPI ag,
Stable downregulation of TFPIβ in MDA-MB-231 breast cancer cells.
% of control
Total/Free TFPI ag
Total TFPI ag,
Free TFPI ag,
Cell growth and colony formation
Effect of downregulation of TFPI on cell motility
The plasminogen activator system, MMP activity, and intracellular signaling
TFPI is mainly recognized for its activity in the coagulation cascade. Previous findings have, however, indicated an additional role of TFPI in cancer biology. We recently showed that shRNA mediated downregulation of TFPI inhibited apoptosis, while ectopic overexpression of TFPI induced apoptosis in breast cancer cells, supporting this hypothesis . In the present study, we demonstrate that stable downregulation of both isoforms of TFPI and TFPIβ alone enhanced the metastatic growth of breast cancer cells by increasing cell spreading, migration and invasion. The phosphorylation status of signaling molecules was affected and elevated MMP-2 and MMP-9 activity was observed that could explain the increased cell invasion. These results further supports an anti-tumor effect of TFPI and indicate a new role of TFPIβ in cancer motility.
The effects of downregulation of TFPI were investigated in the two basal-like invasive breast carcinoma cell types Sum102 and MDA-MB-231. These cells are derived from a primary and a metastatic tumor, respectively, and both express endogenous TFPI; the Sum102 cells approximately four times more than the MDA-MB-231 cells (Table 1). Stable downregulation of TFPI was conducted using RNA interference, and shRNAs targeting both isoforms of TFPI or only TFPIβ, were used. In the MDA-MB-231 cells with TFPIβ downregulated, no decrease in TFPIα antigen was measured verifying that the knockdown was isoform specific. PI-PLC treatment of the transduced cells resulted in the release of TFPI from the cell surface. This was only detectable when total TFPI antigen was measured and confirmed that TFPIβ was attached to the cell surface through a GPI anchor. Also, less TFPI was released in the knockdown cells than in the control cells, which showed that TFPIβ was downregulated at the protein level. The functional effects observed in this study following downregulation of TFPI did not appear to be dose-dependent.
Sum102 cells with TFPI downregulated grew better when seeded at low densities and formed more colonies than control cells. This indicated an increased ability to stimulate self-sufficient growth, both dependent and independent of cell anchorage. Self-sufficient growth signaling often involves changes in expression or activity of growth factors, receptors and signaling molecules in the cells . No increase in cell growth was observed when empty vector control cells were treated with medium taken from knockdown cells seeded at low density (results not shown). This could indicate that the increase in growth signaling was not due to elevated secretion of growth factors but rather to enhanced expression or activity of cell surface receptors and/or signaling molecules. The induced intracellular signaling observed in cells with TFPI downregulated may support this. No effect of downregulation of TFPI was observed on the self-sustained growth of MDA-MB-231 cells in this study. The reason for this is unclear although the two cell types Sum102 and MDA-MB-231 grow at different rates.
The increase in adhesion and stress fiber formation observed in MDA-MB-231 cells to an ECM component indicated that downregulation of TFPI enhanced the integrin-mediated adhesion and -cell spreading of these cells. Moreover, as the increase in adhesion and cell spreading was specific to collagen I, and not to the other ECM components tested, it implied that downregulation of TFPI resulted in enhanced expression and/or activity of collagen I-binding integrins, such as α2β1 . No difference in adhesion to collagen I was measured in the transduced Sum102 cells, although the cells were more extended and an increase in actin stress fiber formation were observed when TFPI was downregulated. This indicated an affect on integrin-mediated cell spreading only. Enhanced protein expression of the α2 integrin subunit was only found in MDA-MB-231 cells after downregulation of TFPI, which may explain the increased adhesion observed in these cells. Provencal and coworkers  previously reported that recombinant TFPI (rTFPI) had no effect on adhesion of U-87 glioblastoma cells to gelatin, which is in line with our results (data not shown). Moreover, in this study rTFPI was reported to have no effect on the migration of brain cancer cells, when the membrane was coated with gelatin.
The molecular mechanisms and processes responsible for the increase in motility observed in cells with TFPI downregulated are not known. The elevated MMP-2 and MMP-9 activity measured in these cells indicated that such proteases are involved in the increased cell invasion detected. Enhanced MMP activity does not, however, explain the increase in adhesion, cell spreading, and migration observed following downregulation of TFPI, and no evidence for the involvement of the plasminogen activator system was found. Thus, other processes not investigated in this study must have been affected. The increase in phosphorylation of an 80 kDa protein and a Src kinase observed in cells with TFPI downregulated may indicate that these signal transduction pathways were involved. TF has been shown to promote tumor cell migration, invasion, growth, and metastasis [36–40], and Hembrough and colleagues  reported that TFPI suppressed metastatic tumor growth in vivo through inhibition of TF/FVIIa activity. Both cell types used in the present study express TF [15, 36], and a possible enhanced TF activity could therefore be responsible for the increased cell motility observed after downregulation of TFPI. In a chromogenic substrate FXa activity assay indirectly measuring cell surface TF activity, we detected an 80-150% increase in TF activity in Sum102, but not in MDA-MB-231, cells with TFPI downregulated (data not shown). This may indicate that elevated TF activity could have been involved in the increased motility of Sum102 knockdown cells. We were, however, unable to detect activation of the MAP kinase cascade in these cell, which is a common downstream effect of TF/FVIIa induced intracellular signaling . It has previously been shown that treatment of brain cancer cells with rTFPI did not affect the phosphorylation status of the MAP kinases ERK1/2 , which is also consistent with our findings.
TFPIα and TFPIβ are the main splice variants transcribed from the TFPI gene but the function of the TFPIβ isoform remains unclear . Surprisingly, downregulation of only TFPIβ in MDA-MB-231 cells resulted in increased cell motility. We recently reported that overexpression of TFPIβ induced apoptosis in SK-BR-3 breast cancer cells , but no effects of TFPIβ on cancer cell motility have previously been published. Our findings therefore support a novel role of TFPIβ in cancer cell metastasis. Compared to TFPIα, TFPIβ lacks the third Kunitz domain and has a different C-terminal end containing a GPI anchor. The importance of the C-terminal part of TFPIα in non-hemostatic activities has previously been reported both in vivo  and in vitro [18–24], and TFPIα has been shown to be able to inhibit cell proliferation by binding to the very low density lipoprotein receptor (VLDLR) through its Kunitz-3 and C-terminal domains . The effects on cell motility observed in the present study after downregulation of TFPIβ indicated, however, that additional mechanisms were involved since TFPIβ lacks the Kunitz-3 domain and has a different C-terminal end than TFPIα. The two isoforms of TFPI share the Kunitz-1 and Kunitz-2 domains and it therefore seems plausible that TFPI induced the anti-tumor effects through association with an unknown receptor, involving the first two Kunitz domains, resulting in the tyrosine phosphorylation of an ~75 kDa protein. However, the similar functional effects observed following downregulation of TFPIβ alone and of both TFPIα and TFPIβ may also indicate that TFPIβ was responsible for most of the effects seen in our study. This was further supported by the low TFPIβ/TFPIα ratio observed in these cells. It is evident that TFPIβ is directly attached to the cell membrane through a GPI anchor (Table 1 and 2, ). GPI anchored proteins are known to be concentrated in areas of the plasma membrane recognized as lipid rafts [42, 43], and the GPI anchor has been reported to be implicated in signal transduction . The Src protein family may also associate with these microdomains and these kinases have been shown to be involved in cell signaling stimulated by GPI anchored molecules . Furthermore, endothelial GPI-bound TFPI has previously been localized to caveolae , which are invaginated lipid rafts . This may indicate that the effect of TFPIβ on cancer cell motility observed in this study could have been mediated through its GPI anchor.
In summary, downregulation of TFPI induced intracellular tyrosine signaling and increased the self-sustained growth and metastatic abilities of breast cancer cell lines in vitro. Increased signal transduction and cell motility was also observed after downregulation of just TFPIβ suggesting a new role for this isoform in cancer metastasis. These results may contribute to new therapeutic approaches in cancer.
Acknowledgements and Funding
This work was funded by research grants form the South-Eastern Norway Regional Health Authority, Hamar, Norway. We would like to thank MSc Ida Evenrød for helpful assistance with the Western blots and Marie-Christine Mowinckel for the FXa measurements.
- Bouillaud S: De l'Obliteration des veines et de son influence sur la formation des hydropisies partielles: consideration sur la hydropisies passive et general. Arch Gen Med. 1823, 1: 188-204.Google Scholar
- Trousseau A: Phlegmasia alba dolens. Clinique medicale de l'Hotel-Dieu de Paris. Edited by: Trousseau A. 1865, Paris: Balliere J.-B.et fils, 654-712. 2Google Scholar
- Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW: Cancer and thrombosis: from molecular mechanisms to clinical presentations. J Thromb Haemost. 2007, 5: 246-254.View ArticlePubMedGoogle Scholar
- Bajaj MS, Birktoft JJ, Steer SA, Bajaj SP: Structure and biology of tissue factor pathway inhibitor. Thromb Haemost. 2001, 86: 959-972.PubMedGoogle Scholar
- Price GC, Thompson SA, Kam PCA: Tissue factor and tissue factor pathway inhibitor. Anaesthesia. 2004, 59: 483-492. 10.1111/j.1365-2044.2004.03679.x.View ArticlePubMedGoogle Scholar
- Lindahl AK, Sandset PM, Abildgaard U, Andersson TR, Harbitz TB: High Plasma-Levels of Extrinsic Pathway Inhibitor and Low-Levels of Other Coagulation Inhibitors in Advanced Cancer. Acta Chir Scand. 1989, 155: 389-393.PubMedGoogle Scholar
- Iversen N, Lindahl AK, Abildgaard U: Elevated TFPI in malignant disease: relation to cancer type and hypercoagulation. Br J Haematol. 1998, 102: 889-895. 10.1046/j.1365-2141.1998.00875.x.View ArticlePubMedGoogle Scholar
- Kurer MA: Protein and mRNA expression of tissue factor pathway inhibitor-1 (TFPI-1) in breast, pancreatic and colorectal cancer cells. Mol Biol Rep. 2007, 34: 221-224. 10.1007/s11033-006-9036-4.View ArticlePubMedGoogle Scholar
- Sierko E, Wojtukiewicz MZ, Zimnoch L, Kisiel W: Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue. Thromb Haemost. 2010, 103: 198-204.View ArticlePubMedGoogle Scholar
- Lwaleed BA, Bass PS: Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol. 2006, 208: 327-339. 10.1002/path.1871.View ArticlePubMedGoogle Scholar
- Zhang J, Piro O, Lu L, Broze GJ: Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation. 2003, 108: 623-627. 10.1161/01.CIR.0000078642.45127.7B.View ArticlePubMedGoogle Scholar
- Maroney SA, Cunningham AC, Ferrel J, Hu R, Haberichter S, Mansbach CM, Brodsky RA, Dietzen DJ, Mast AE: A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression. J Thromb Haemost. 2006, 4: 1114-1124. 10.1111/j.1538-7836.2006.01873.x.View ArticlePubMedGoogle Scholar
- Piro O, Broze GJ: Comparison of cell-surface TFPI alpha and beta. J Thromb Haemost. 2005, 3: 2677-2683. 10.1111/j.1538-7836.2005.01636.x.View ArticlePubMedGoogle Scholar
- Crawley JTB, Lane DA: The Haemostatic Role of Tissue Factor Pathway Inhibitor. Arterioscler Thromb Vasc Biol. 2008, 28: 233-242.View ArticlePubMedGoogle Scholar
- Stavik B, Skretting G, Sletten M, Sandset PM, Iversen N: Overexpression of both TFPIalpha and TFPIbeta induces apoptosis and expression of genes involved in the death receptor pathway in breast cancer cells. Mol Carcinog. 2010, 49: 951-963. 10.1002/mc.20679.View ArticlePubMedGoogle Scholar
- Hembrough TA, Swartz GM, Papathanassiu A, Vlasuk GP, Rote WE, Green SJ, Pribluda VS: Tissue Factor/Factor VIIa Inhibitors Block Angiogenesis and Tumor Growth Through a Nonhemostatic Mechanism. Cancer Res. 2003, 63: 2997-3000.PubMedGoogle Scholar
- Amirkhosravi A, Meyer T, Chang JY, Amaya M, Siddiqui F, Desai H, Francis JL: Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost. 2002, 87: 930-936.PubMedGoogle Scholar
- Hamuro T, Kamikubo Y, Nakahara Y, Miyamoto S, Funatsu A: Human recombinant tissue factor pathway inhibitor induces apoptosis in cultured human endothelial cells. FEBS Lett. 1998, 421: 197-202. 10.1016/S0014-5793(97)01559-7.View ArticlePubMedGoogle Scholar
- Hembrough TA, Ruiz JF, Papathanassiu AE, Green SJ, Strickland DK: Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem. 2001, 276: 12241-12248. 10.1074/jbc.M010395200.View ArticlePubMedGoogle Scholar
- Kamikubo Yi, Nakahara Y, Takemoto S, Hamuro T, Miyamoto S, Funatsu A: Human recombinant tissue-factor pathway inhibitor prevents the proliferation of cultured human neonatal aortic smooth muscle cells. FEBS Lett. 1997, 407: 116-120. 10.1016/S0014-5793(97)00312-8.View ArticlePubMedGoogle Scholar
- Liang W, Cheng J, Liu R, Wang Jp, Mu Jg, Wang Qh, Wang Hj, Ma D: Peptide corresponding to the C terminus of tissue factor pathway inhibitor inhibits mesangial cell proliferation and activation in vivo. Peptides. 2009, 30: 2330-2336. 10.1016/j.peptides.2009.08.016.View ArticlePubMedGoogle Scholar
- Lin YF, Zhang N, Guo HS, Kong DS, Jiang T, Liang W, Zhao ZH, Tang QQ, Ma D: Recombinant tissue factor pathway inhibitor induces apoptosis in cultured rat mesangial cells via its Kunitz-3 domain and C-terminal through inhibiting PI3-kinase/Akt pathway. Apoptosis. 2007, 12: 2163-2173. 10.1007/s10495-007-0136-y.View ArticlePubMedGoogle Scholar
- Shirotani-Ikejima H, Kokame K, Hamuro T, Bu G, Kato H, Miyata T: Tissue factor pathway inhibitor induces expression of JUNB and GADD45B mRNAs. Biochem Biophys Res Commun. 2002, 299: 847-852. 10.1016/S0006-291X(02)02759-6.View ArticlePubMedGoogle Scholar
- Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS: Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood. 2004, 103: 3374-3380. 10.1182/blood-2003-07-2234.View ArticlePubMedGoogle Scholar
- Hanahan D, Weinberg RA: The hallmarks of cancer. Cell. 2000, 100: 57-70. 10.1016/S0092-8674(00)81683-9.View ArticlePubMedGoogle Scholar
- Felding-Habermann B: Integrin adhesion receptors in tumor metastasis. Clin Exp Metastasis. 2003, 20: 203-213. 10.1023/A:1022983000355.View ArticlePubMedGoogle Scholar
- Panetti TS: Tyrosine phosphorylation of paxillin, FAK, and p130CAS: Effects on cell spreading and migration. Front Biosci. 2002, 7: D143-D150. 10.2741/panetti.PubMedGoogle Scholar
- Defilippi P, Olivo C, Venturino M, Dolce L, Silengo L, Tarone G: Actin cytoskeleton organization in response to integrin-mediated adhesion. Microsc Res Tech. 1999, 47: 67-78. 10.1002/(SICI)1097-0029(19991001)47:1<67::AID-JEMT7>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
- Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997, 89: 1260-1270. 10.1093/jnci/89.17.1260.View ArticlePubMedGoogle Scholar
- Storvold GL, Gjernes E, Askautrud HA, Borresen-Dale AL, Perou CM, Frengen E: A retroviral vector for siRNA expression in mammalian cells. Mol Biotechnol. 2007, 35: 275-282. 10.1007/BF02686013.View ArticlePubMedGoogle Scholar
- Winberg JO, Berg E, Kolset SO, Uhlin-Hansen L: Calcium-induced activation and truncation of promatrix metalloproteinase-9 linked to the core protein of chondroitin sulfate proteoglycans. Eur J Biochem. 2003, 270: 3996-4007. 10.1046/j.1432-1033.2003.03788.x.View ArticlePubMedGoogle Scholar
- McCall-Culbreath KD, Zutter MM: Collagen receptor integrins: Rising to the challenge. Curr Drug Targets. 2008, 9: 139-149. 10.2174/138945008783502494.View ArticlePubMedGoogle Scholar
- Stefansson S, Lawrence DA: Old Dogs and New Tricks, Proteases, Inhibitors, and Cell Migration. Sci STKE. 2003, 2003: e24-Google Scholar
- Andreasen PA, Egelund R, Petersen HH: The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci. 2000, 57: 25-40. 10.1007/s000180050497.View ArticlePubMedGoogle Scholar
- Provencal M, Michaud M, Beaulieu E, Ratel D, Rivard GE, Gingras D, Beliveau R: Tissue factor pathway inhibitor (TFPI) interferes with endothelial cell migration by inhibition of both the Erk pathway and focal adhesion proteins. Thromb Haemost. 2008, 99: 576-585.PubMedGoogle Scholar
- Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, Pendurthi UR, Rao LV: Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004, 103: 3029-3037. 10.1182/blood-2003-10-3417.View ArticlePubMedPubMed CentralGoogle Scholar
- Kakkar AK, Chinswangwatanakul V, Lemoine NR, Tebbutt S, Williamson RC: Role of tissue factor expression on tumour cell invasion and growth of experimental pancreatic adenocarcinoma. Br J Surg. 1999, 86: 890-894. 10.1046/j.1365-2168.1999.01153.x.View ArticlePubMedGoogle Scholar
- Yu JL, May L, Lhotak V, Shahrzad S, Shirasawa S, Weitz JI, Coomber BL, Mackman N, Rak JW: Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis. Blood. 2005, 105: 1734-1741. 10.1182/blood-2004-05-2042.View ArticlePubMedGoogle Scholar
- Versteeg HH, Schaffner F, Kerver M, Petersen HH, Ahamed J, Felding-Habermann B, Takada Y, Mueller BM, Ruf W: Inhibition of tissue factor signaling suppresses tumor growth. Blood. 2008, 111: 190-199. 10.1182/blood-2007-07-101048.View ArticlePubMedPubMed CentralGoogle Scholar
- Ngo CV, Picha K, McCabe F, Millar H, Tawadros R, Tam SH, Nakada MT, Anderson GM: CNTO 859, a humanized anti-tissue factor monoclonal antibody, is a potent inhibitor of breast cancer metastasis and tumor growth in xenograft models. Int J Cancer. 2007, 120: 1261-1267. 10.1002/ijc.22426.View ArticlePubMedGoogle Scholar
- Versteeg HH, Spek CA, Peppelenbosch MP, Richel DJ: Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathways. Mol Med. 2004, 10: 6-11. 10.1007/s00894-003-0157-6.View ArticlePubMedPubMed CentralGoogle Scholar
- Trotter J, Klein C, Kramer EM: GPI-anchored proteins and glycosphingolipid-rich rafts: Platforms for adhesion and signaling. Neuroscientist. 2000, 6: 271-284. 10.1177/107385840000600410.View ArticleGoogle Scholar
- Horejsi V, Drbal K, Cebecauer M, Cerny J, Brdicka T, Angelisova P, Stockinger H: GPI-microdomains: a role in signalling via immunoreceptors. Immunol Today. 1999, 20: 356-361. 10.1016/S0167-5699(99)01489-9.View ArticlePubMedGoogle Scholar
- Paulick MG, Bertozzi CR: The glycosylphosphatidylinositol anchor: a complex membrane-anchoring structure for proteins. Biochemistry. 2008, 47: 6991-7000. 10.1021/bi8006324.View ArticlePubMedPubMed CentralGoogle Scholar
- Stefanova I, Horejsi V, Ansotegui IJ, Knapp W, Stockinger H: GPI-Anchored Cell-Surface Molecules Complexed to Protein Tyrosine Kinases. Science. 1991, 254: 1016-1019. 10.1126/science.1719635.View ArticlePubMedGoogle Scholar
- Lupu C, Goodwin CA, Westmuckett AD, Emeis JJ, Scully MF, Kakkar VV, Lupu F: Tissue factor pathway inhibitor in endothelial cells colocalizes with glycolipid microdomains/caveolae. Regulatory mechanism(s) of the anticoagulant properties of the endothelium. Arterioscler Thromb Vasc Biol. 1997, 17: 2964-2974. 10.1161/01.ATV.17.11.2964.View ArticlePubMedGoogle Scholar
- Simons K, Toomre D: Lipid rafts and signal transduction. Nat Rev Mol Cell Biol. 2000, 1: 31-39. 10.1038/35036052.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/11/357/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.